Advanced search
Publication Cover
Hematology Volume 29, 2024 - Issue 1
Submit an article Journal homepage
563
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Endari treatment ameliorates sickle cell-related disruption in intestinal barrier functions and is associated with prolonged survival in sickle cell mice

Elio HarounDivision of Hematology and Oncology, Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USAView further author information
,
Seah H. LimDivision of Hematology and Oncology, Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USAView further author information
&
Dibyendu DuttaDivision of Hematology and Oncology, Department of Medicine, SUNY Upstate Medical University, Syracuse, NY, USACorrespondence[email protected]
View further author information
Article: 2331940 | Received 13 Nov 2023, Accepted 13 Mar 2024, Published online: 25 Mar 2024

References

  • Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of L-glutamine in sickle cell disease. N Engl J Med. 2018;379:226–235. doi:10.1056/NEJMoa1715971
  • Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381:509–519. doi:10.1056/NEJMoa1903212
  • Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376:429–439. doi:10.1056/NEJMoa1611770
  • Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645. doi:10.1001/jama.289.13.1645
  • Araujo OMRD, Ivo ML, Ferreira Júnior MA, et al. Survival and mortality among users and non-users of hydroxyurea with sickle cell disease. Rev Latino-Am Enfermagem. 2015;23:67–73. doi:10.1590/0104-1169.3385.2526
  • Niihara Y, Zerez CR, Akiyama DS, et al. Increased red cell glutamine availability in sickle cell anemia: demonstration of increased active transport, affinity, and increased glutamate level in intact red cells. J Lab Clin Med. 1997;130:83–90. doi:10.1016/S0022-2143(97)90062-7
  • Niihara Y, Zerez CR, Akiyama DS, et al. Oral L-glutamine therapy for sickle cell anemia: I. subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol. 1998;58:117–121. doi:10.1002/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V
  • Niihara Y, Matsui NM, Shen YM, et al. L-Glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Hematol. 2005;5:4. doi:10.1186/1471-2326-5-4
  • Poplawska M, Dutta D, Jayaram M, et al. Intestinal pathophysiological abnormalities in steady state and after vaso-occlusive crisis in murine sickle cell disease. Br J Haematol. 2022;196:777–780. doi:10.1111/bjh.17889
  • Thein MS, Igbineweka NE, Thein SL. Sickle cell disease in the older adult. Pathology. 2017;49:1–9. doi:10.1016/j.pathol.2016.10.002
  • Haroun E, Dutta D, Lim SH. Effects of GBT1118, a voxelotor analog, on intestinal pathophysiology in sickle cell disease. Br J Haematol. 2023;202:184–194. doi:10.1111/bjh.18813
  • Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med. 1995;332:1317–1322. doi:10.1056/NEJM199505183322001
  • Brandow AM, Panepinto JA. Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities. Expert Rev Hematol. 2010;3:255–260. doi:10.1586/ehm.10.22
  • Elenga N, Loko G, Etienne-Julan M, et al. Real-world data on efficacy of L-glutamine in preventing sickle cell disease-related complications in pediatric and adult patients. Front Med. 2022;9:931925. doi:10.3389/fmed.2022.931925
  • Jafri F, Seong G, Jang T, et al. L-glutamine for sickle cell disease: more than reducing redox. Ann Hematol. 2022;101:1645–1654. doi:10.1007/s00277-022-04867-y
  • Dutta D, Methe B, Amar S, et al. Intestinal injury and gut permeability in sickle cell disease. J Transl Med. 2019;17:183. doi:10.1186/s12967-019-1938-8
  • Poplawska M, Dutta D, Jayaram M, et al. Genes modulating intestinal permeability and microbial community are dysregulated in sickle cell disease. Ann Hematol. 2022;101:1009–1013. doi:10.1007/s00277-022-04794-y
  • Zhang D, Chen G, Manwani D, et al. Neutrophil ageing is regulated by the microbiome. Nature. 2015;525:528–532. doi:10.1038/nature15367
  • Dutta D, Methe BA, Morris A, et al. Effects of rifaximin on circulating aged neutrophils in sickle cell disease. Am J Hematol. 2019;94. doi:10.1002/ajh.25467
  • Lim SH, Dutta D, Moore J. Rifaximin for sickle cell disease. Am J Hematol. 2019;94. doi:10.1002/ajh.25637
  • Dutta D, Li K, Methe B, et al. Rifaximin on intestinally-related pathologic changes in sickle cell disease. Am J Hematol. 2020;95. doi:10.1002/ajh.25722
  • Curi R, Newsholme P, Marzuca-Nassr GN, et al. Regulatory principles in metabolism–then and now. Biochem J. 2016;473:1845–1857. doi:10.1042/BCJ20160103
  • Souba WW. Glutamine: a key substrate for the splanchnic bed. Annu Rev Nutr. 1991;11:285–308. doi:10.1146/annurev.nu.11.070191.001441
  • Huang Y, Shao XM, Neu J. Immunonutrients and neonates. Eur J Pediatr. 2003;162:122–128. doi:10.1007/s00431-002-1128-0

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.